The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses. Its purpose…
Citius enters partnership for Phase I/Ib solid tumour treatment trial
The trial will evaluate the variation in the immune microenvironment within tumours, as well as in the peripheral blood. Citius Pharmaceuticals has entered a clinical partnership with the University of Pittsburgh for a Phase I/Ib trial of I/ONTAK (denileukin diftitox…
AEON reports positive data from Phase II cervical dystonia treatment trial
All three tested doses of ABP-450 were found to be generally safe and well tolerated. AEON Biopharma has reported positive topline data from its Phase II clinical trial of ABP-450 (prabotulinumtoxinA) to treat cervical dystonia (CD). The double-blind, randomised, placebo-controlled…
Positive Phase III lecanemab data for contested Alzheimer’s disease target
Eisai and Biogen reported that lecanemab met the primary endpoint as well as all key secondary endpoints of the trial with statistical significance. Eisai and Biogen reported positive data from a Phase III clinical trial of the anti-amyloid antibody lecanemab…
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
TOKYO and CENTER VALLEY, PA., Sept 28, 2022 – (JCN Newswire) – Olympus Corporation (Olympus), a global medtech company committed to making people’s lives healthier, safer, and more fulfilling, today announced the release of the THUNDERBEAT(TM) Open Fine Jaw Type X surgical energy devices…
First human data backs Calibr/AbbVie’s “switchable” CAR-T therapy
California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses “switchable” cells that aim to eliminate the life-threatening side-effects that can occur with this type of immunotherapy. Like other CAR-Ts, Calibr’s…
Genfit builds rare liver disease pipeline with Versantis buy
French pharma company Genfit has reached a deal to buy Versantis of Switzerland, adding three development-stage drug candidates to its portfolio of experimental liver disease therapies and continuing a strategy change first unveiled in 2020. That change was forced by…
Why does your address raise your risk of heart attack? AI seeks answers
It’s well known that where you live can have a profound impact on your risk of heart attack or stroke, but the exact reasons behind that inequality can be hard to tease out. Now, a collaboration between drugmaker Novartis, Microsoft,…
Hope for lupus sufferers with Feinstein Institutes-led phase 2 trial
Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic…
Otsuka, Aurinia claim EU okay for oral lupus nephritis drug
Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus erythematosus. Kidney inflammation caused by SLE is referred to as…
